

ASX ANNOUNCEMENT

Vitura raises \$5.1 million from Professor Khalil (Charlie) Shahin AO

12 FEBRUARY 2025

Melbourne, Australia – Vitura Health Limited (ASX: VIT) (**Vitura and Company**), a leading digital health platform business focused on innovating the delivery of healthcare by building a centralised healthcare experience, is pleased to announce that it has executed a Share Subscription Agreement with AFO Investments Pty Ltd, as Trustee for the AFO Investment Trust (**AFO**), an entity associated with South Australian based high-net-worth investor Professor Khalil (Charlie) Shahin AO to invest \$5,171,196 in Vitura (**Placement**).

Professor Shahin is best known as the Managing Director of Peregrine Corporation, one of Australia's largest privately owned companies. Born in Beirut, Lebanon, Professor Shahin moved to Australia and co-founded Peregrine Corporation with his father in 1984. The company has since grown significantly, employing over 7,000 staff and generating an annual turnover of approximately \$2.7 billion. In 2023, Peregrine Corporation sold its OTR Group, including petrol stations and convenience stores, to Viva Energy for \$1.15 billion. In 2017, Professor Shahin was honoured as an Officer of the Order of Australia for his distinguished service to business, corporate social responsibility, and support for the multicultural community.

The Company has issued a total of 74,814,757 ordinary shares (**Shares**) to AFO. The shares were issued at a price of \$0.06912 per share, being a 10% discount to the five-day volume weighted average price of the Company's shares on 31 January 2025. Importantly, no additional fees will be paid by the Company in respect of the Placement. As a result, the Company has raised a total of \$5,171,196 from the Placement. The Shares owned by AFO represent 11.4% of the Company's total issued capital. The new Shares issued will utilise the Company's existing capacity under ASX Listing Rule 7.1 and no shareholder approval is required.

The placement funds will be used by the Company to fund the \$4 million initial cash component associated with the purchase of Candor Medical, as announced by the Company on 12 February 2025, with the remainder to fund the Company's future expansion plans. The Company is confident that the acquisition of Candor Medical will deliver a material increase in Vitura's revenues and EBITDA in FY2025 and beyond. Further, the anticipated increase in EBITDA resulting from the acquisition of Candor will deliver a significant increase in earnings per share for the Company post the placement of shares to AFO.

Vitura Chair, Robert Iervasi, said *"Vitura is very pleased to be welcoming an experienced and proven business leader like Charlie Shahin as a substantial shareholder in the Company. As a major shareholder of the Company, Charlie will bring to Vitura a wealth of experience. Charlie's investment is an important validation of the potential of Vitura and our Strategy Reset, and the importance of providing patients with options in how they access healthcare in Australia."*

Professor Shahin said *"I am delighted in becoming a major shareholder in Vitura. The business is well positioned for growth and I look forward to supporting Vitura in its growth platforms."*

Upon the release of this announcement, the current Trading Halt pertaining to the Company's shares will be lifted.

** ENDS **

VITURA HEALTH LIMITED

ASX: VIT

PO Box 6168, South Yarra

Victoria 3141, Australia

VITURA.COM.AU





About Vitura Health Limited (ASX: VIT)

www.vitura.com.au

Vitura Health Limited is diversified digital health business listed on the ASX (ASX: VIT) and, via its wholly owned subsidiaries, operates the following businesses:

- www.burleighheadscannabis.com
Burleigh Heads Cannabis operates the market leading prescriber, patient, pharmacy, and supplier online ecosystem, Canview, which sells and distributes 430+ therapeutic product and device SKUs within Australia from roughly 60 international and domestic brands.
- www.canview.com.au
Canview is being developed to be a complete end-to-end healthcare ecosystem designed to provide doctors, pharmacists, and patients with a simple and cost-effective way to facilitate the treatment of patients with increased efficiency and compliance. The Canview system is based on a medicines wholesaling platform which seamlessly brings together several disparate SAAS (software-as-a-service) providers including inventory control, invoicing, customer management, reporting and analytics, all linked together through customised integration from third party providers. Underpinning the suite of SAAS elements are several bespoke, internally generated operating procedures and intellectual property assets, supported by the Canview customer support and infield customer engagement teams. Through the integration of the different elements which together make up Canview, the platform provides the best user experience in the industry.

Through the Company's relationships with third party integrators, Canview provides Australian doctors with the ability to integrate their patient management systems directly with the platform and to use their patient information to generate electronic prescriptions within the Canview platform, without the need to input the patient's details. Prescriptions are then sent directly to the Canview patient app where patients can manage their treatment and submit the prescription and subsequent repeats to one of the nearly 4,500 Australian pharmacies with accounts on Canview for dispensing.

While the Company's current operations focus on the sale and distribution of medicinal cannabis products, Vitura is fully licensed and equipped, via its two state-of-the-art distribution centres in Melbourne and the Gold Coast, to distribute all products under Schedules 2, 3, 4, 8 and 9. The establishment during the year of the Company's joint venture to distribute psychedelic products, including MDMA and Psilocybin, is a timely example of the many opportunities that the Company believes can be seamlessly integrated into its existing digital health platform business.

- www.doctorsondemand.com.au
The Company owns Doctors on Demand Pty Ltd, a nationwide 24/7 x 365 telehealth platform business that provide innovative primary health solutions to hundreds of thousands of B2C and B2B patients annually. Services include general medical consults, urgent care, medical certificates, pathology referrals, specialist referrals, men's health, women's health, medicated weight loss and smoking cessation.
- www.cortexa.com.au
The Company owns 50% of Cortexa Pty Ltd, an incorporated joint venture with Canadian-based PharmAla Biotech (CSE: MDMA). Cortexa aims to be the leading supplier of psychedelics, GMP MDMA and GMP psilocybin, for research and therapeutic use in Australia.
- www.cdaclinics.com.au
The Company owns CDA Clinics that undertakes nationwide telehealth consultations with patients seeking access to medicinal cannabis.
- www.cannadoc.com.au
The Company owns 75.5% of Cannadoc Health Pty Ltd, a medicinal cannabis clinic business that undertakes nationwide telehealth consultations with patients seeking access to medicinal cannabis.



Authorised by

Robert Iervasi, Chair and Non-Executive Director

Contact

Vitura Health Limited

Robert Iervasi
Chair
1300 799 491
info@vitura.com.au

Media enquiries

Dieter Lehmann
Nominis Communications
+61 427 672 995
dieter@nominis.me

Forward-looking statements

This announcement includes forward-looking statements which may be identified by words such as 'anticipates', 'believes', 'expects', 'intends', 'may', 'will', 'could', or 'should' and other similar words that involve risks and uncertainties. These forward-looking statements are based on the Company's expectations and beliefs concerning future events as at the date of this announcement. Forward-looking statements are necessarily subject to risks, uncertainties, and other factors, many of which are outside the control of the Company, which could cause actual results to differ materially from such statements. The Company makes no undertaking to update or revise the forward-looking statements made in this announcement to reflect any change in circumstances or events after the date of this announcement.